Compare SSBI & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | ICCC |
|---|---|---|
| Founded | 1982 | 1982 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6M | 93.1M |
| IPO Year | N/A | 1995 |
| Metric | SSBI | ICCC |
|---|---|---|
| Price | $12.87 | $10.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 28.5K |
| Earning Date | 04-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.23 | $24.00 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $10.35 | $4.52 |
| 52 Week High | $14.00 | $12.10 |
| Indicator | SSBI | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 38.02 |
| Support Level | $12.77 | $9.36 |
| Resistance Level | $13.61 | $10.75 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 49.04 | 18.87 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.